NCT01811212 - Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2013

Primary Completion Date

July 13, 2015

Study Completion Date

October 9, 2017

Conditions

Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular CarcinomaStage I Thyroid Gland Papillary CarcinomaStage II Thyroid Gland Follicular CarcinomaStage II Thyroid Gland Papillary CarcinomaStage III Thyroid Gland Follicular CarcinomaStage III Thyroid Gland Papillary CarcinomaStage IVA Thyroid Gland Follicular CarcinomaStage IVA Thyroid Gland Papillary CarcinomaStage IVB Thyroid Gland Follicular CarcinomaStage IVB Thyroid Gland Papillary CarcinomaStage IVC Thyroid Gland Follicular CarcinomaStage IVC Thyroid Gland Papillary CarcinomaTall Cell Variant Thyroid Gland Papillary CarcinomaThyroid Gland Oncocytic Follicular Carcinoma

Interventions

DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (7)

20007

MedStar Georgetown University Hospital, Washington D.C.

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic, Rochester

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

M D Anderson Cancer Center, Houston

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston